HCA
CLB icon

Harpswell Capital Advisors’s Core Laboratories CLB Stock Holding History

Harpswell Capital Advisors’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
+11,654
New +$166K 0.09% 46

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harpswell Capital Advisors's CLB Position: Q2 2026 in Review

Harpswell Capital Advisors opened a new position in Core Laboratories (CLB) in Q2 2026: 11,654 shares worth $136K. The stake represents 0.09% of the portfolio and ranks #46 among its holdings.

186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • Harpswell Capital Advisors held 11,654 shares of Core Laboratories worth $136K as of Q2 2026.
  • Core Laboratories was a new Harpswell Capital Advisors position in Q2 2026.
  • Core Laboratories made up 0.09% of Harpswell Capital Advisors's portfolio in Q2 2026, its #46 holding.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Harpswell Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.